Atlas Arteria Limited has been removed from the S&P/ASX 100 Index following S&P Dow Jones Indices’ September 2026 quarterly rebalance announcement, with the change effective prior to market open on Monday, September 21, 2026. Codan Limited takes the inclusion slot, marking a straightforward one-for-one rotation within the mid-cap segment of Australia’s benchmark indices. This is the headline move for ALX holders and carries practical implications for index fund positioning.
Index inclusion changes typically influence a stock’s trading profile and investor base composition. Removal from the ASX 100 generally results in selling pressure in the period surrounding the rebalance execution date, driven by passive index funds and exchange-traded funds that track the index and must rebalance their holdings accordingly. The magnitude of these flows depends partly on the size and composition of funds tracking the ASX 100 specifically, versus those following broader indices such as the ASX 200 or 300, into which ALX remains included. This distinction matters significantly for how much mechanical selling pressure the stock may face.
The broader quarterly rebalance reflects the standard index review process. The ASX 20 remained unchanged, while the ASX 50 saw two removals including WiseTech Global and Cochlear, with Mineral Resources and NEXTDC added. The ASX 200 experienced more substantial churn with multiple additions and removals across sectors, while the ASX 300 incorporated fifteen new constituents and fourteen removals. The All Ordinaries index showed the most activity, with numerous junior listings joining and others exiting. These rotations underscore the fluid nature of index composition as market capitalizations and rankings shift.
For Atlas Arteria investors, the practical impact depends on their fund managers’ tracking strategies and mandate. Those holding the stock through passive ASX 100 tracking strategies will see their holdings adjust on September 21, while investors in strategies tracking the ASX 200 or 300 will experience no forced changes. The removal may also result in slightly reduced liquidity and analyst coverage in the near term, as index-tracking funds exit their positions and capital seeks exposure elsewhere.
Market participants should monitor Atlas Arteria’s trading volume and price action in the lead-up to September 21, particularly if the stock experiences weakness attributable to rebalance-driven flows. The removal from ASX 100 is a technical adjustment rather than a reflection of fundamental company deterioration. Investors with long-term conviction may view the pressure created by mechanical index adjustments as a potential entry point. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About Atlas Arteria Limited (ASX: ALX)
Atlas Arteria Limited is a global owner, operator, and developer of toll roads with a portfolio spanning France, Germany, and the United States. The company holds significant interests in major toll road networks including approximately 31% of the APRR motorway network in eastern France, the Warnow Tunnel in Germany, the Chicago Skyway in the United States, and full ownership of the Dulles Greenway in Virginia. The company is based in Melbourne, Australia and operates toll road businesses that generate revenue from motorway usage across multiple countries.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
